重组人表皮生长因子凝胶联合赛肤润对慢性伤口患者疼痛评分及不良反应的影响  

Effect of Recombinant Human Epidermal Growth Factor Gel Combined with Saifurun on Pain Scores and Adverse Reactions in Patients with Chronic Wounds

作　　者：黄丽娟[1] 成晓凤 颜建辉[3] 雷冠雄[4] 韩焱 黄克敏[5] HUANG Li-juan;CHENG Xiao-feng;YAN Jian-hui;LEI Guan-xiong;HAN Yan;HUANG Ke-min(Gastrointestinal Surgery,Affiliated Hospital of Xiangnan University,Chenzhou,Hunan,423000,China;Operating Room,Affiliated Hospital of Xiangnan University,Chenzhou,Hunan,423000,China;Department of Geriatrics,Affiliated Hospital of Xiangnan University,Chenzhou,Hunan,423000,China;Department of Otorhinolaryngology Head and Neck Surgery,Affiliated Hospital of Xiangnan University,Chenzhou,Hunan,423000,China;Department of Orthopedics,Affiliated Hospital of Xiangnan University,Chenzhou,Hunan,423000,China)

机构地区：[1]湘南学院附属医院胃肠外科,湖南郴州423000 [2]湘南学院附属医院手术室,湖南郴州423000 [3]湘南学院附属医院老年医学科,湖南郴州423000 [4]湘南学院附属医院耳鼻喉头颈外科,湖南郴州423000 [5]湘南学院附属医院骨科,湖南郴州423000

出　　处：《现代生物医学进展》2021年第18期3529-3532,共4页Progress in Modern Biomedicine

基　　金：湖南省自然科学基金科卫联合项目(2020JJ8034)。

摘　　要：目的:探讨重组人表皮生长因子(Recombinant human epidermal growth factor,rhEGF)凝胶联合赛肤润对慢性伤口患者疗效及对疼痛评分与不良反应的影响。方法:2017年3月-2019年9月选择在本院进行诊治的胃肠外科术后慢性伤口患者108例,根据治疗方法分为联合组与对照组各54例。对照组给予赛肤润治疗,联合组在对照组治疗的基础上给予rhEGF凝胶治疗,两组都持续给药观察14 d,记录患者疼痛与不良反应情况。结果:联合组治疗第3 d、第7 d、第14 d的疼痛VAS评分都低于对照组(P<0.05)。联合组治疗期间的皮肤坏死、伤口感染、发热等不良反应发生率为3.7%,低于对照18.5%(P<0.05)。联合组治疗后第3 d伤口愈合率为83.3%,高于对照组的59.3%(P<0.05),治疗后第7 d、第14 d的联合组伤口愈合率稍高于对照组,对比无统计学意义(P>0.05)。两组治疗后的血清血管内皮生长因子(vascular endothelial growth factor,VEGF)含量高于治疗前(P<0.05),联合组高于对照组(P<0.05)。结论:rhEGF凝胶联合赛肤润在慢性伤口患者的应用能促进缓解疼痛评分,减少不良反应的发生,促进VEGF的表达,从而加快伤口愈合。Objective:To investigate the effects of recombinant human epidermal growth factor(rhEGF)gel combined with Saifurun on pain scores and adverse reactions in patients with chronic wounds.Methods:A total of 108 patients with chronic wounds after gastrointestinal surgery,who were diagnosed and treated in Affiliated Hospital of Xiangnan University from March 2017 to September2019,were chosen and were divided into combination group(n=54)and control group(n=54).The control group was given Saifurun treatment,and the combination group was given rhEGF gel treatment on the basis of the control group’s therapy.The two groups were given continuous administration for 14 days,and the pain and adverse reactions were recorded.Results:The pain VAS scores on the 3 rd,7 th,and 14 th days after treatment of the combination group were lower than those of the control group(P<0.05).The incidence(3.7%)of skin necrosis,wound infection,fever and other adverse reactions during treatment in the combination group was lower than that(18.5%)in the control group(P<0.05).The wound healing rates of the combination group on the 3 rd,7 th,and 14 th days were 83.3%,96.3%and100.0%,which were higher than those(59.3%,83.3%and 88.9%)of the control group(P<0.05).The serum vascular endothelial growth factor(VEGF)levels after treatment in the two groups were higher than those before treatment(P<0.05),and the combination group was higher than the control group(P<0.05).Conclusion:The application of rhEGF gel combined with Saifurun in the patients with chronic wounds can promote pain relief scores,reduce the occurrence of adverse reactions,promote the expression of VEGF,and accelerate wound healing.

关 键 词：重组人表皮生长因子凝胶 赛肤润 慢性伤口 疼痛 不良反应 

分 类 号：R605[医药卫生—外科学] R758.7[医药卫生—临床医学]